--Wells Fargo Adjusts Price Target on Avidity Biosciences to $50 From $55, Maintains Overweight Rating

--Wells Fargo Adjusts Price Target on Avidity Biosciences to $50 From $55, Maintains Overweight Rating

MT Newswires · 05/11/2023 06:56

Please log in to view news